PT  - JOURNAL ARTICLE
AU  - Madelene Adele Young
TI  - Lymphoscintigraphic Mapping Advancement for Melanoma and Breast Cancer
AID  - 10.2967/jnmt.120.246918
DP  - 2020 Sep 01
TA  - Journal of Nuclear Medicine Technology
PG  - jnmt.120.246918
4099  - http://tech.snmjournals.org/content/early/2020/09/03/jnmt.120.246918.short
4100  - http://tech.snmjournals.org/content/early/2020/09/03/jnmt.120.246918.full
AB  - This paper combines the research and experience of ten recognized authors and publishers to analyze results and conclusions in the realm of lymphoscintigraphy. Many different radiopharmaceuticals have been used while determining the best option. Results of the studies and comparison to other similar procedures for lymph node mapping (LNM) is made. Sentinel lymph node (SLN) involvement and stage of the disease is characterized as variable and is explained, in detail, throughout this paper. There are varying opinions on the best route of administration, length of delay images and radiopharmaceutical to use. All of the discrepancies between protocols are supported with evidence such as positive results or false positive results. This paper will illustrate the different preferences of the procedure and the generally accepted protocols of the best way to locate the SLN. The series of images that are taken in lymphoscintigraphy must be sensitive enough to pick up on the SLN yet quickly clear from healthy lymph channels in order to distinguish the SLN from lymph channels. This creates a debate around which radiopharmaceutical is best for this study. Upon reading this paper, you will be able to form an opinion of the best protocols and radiopharmaceuticals based on the facts, all while seeing how lymphoscintigraphy is a crucial tool in taking steps to improve a patient’s prognosis.